import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "how-to-use-ipamorelin-research-protocol-guide",
  title: "How to Use Ipamorelin: Research Protocol Guide (2026)",
  description:
    "A comprehensive research protocol reference for Ipamorelin — covering reconstitution, administration routes, dosing windows, GH axis endpoints, and study design considerations from preclinical literature.",
  category: "Research Protocols",
  readMinutes: 9,
  publishedAt: "2026-06-20",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor (GHS-R1a). Its high selectivity for GH release over cortisol, ACTH, and prolactin has made it one of the most studied GHS compounds in preclinical research since its characterization in the late 1990s. This guide covers the practical steps for researchers designing Ipamorelin protocols.",
    },
    {
      type: "callout",
      text: "This guide is for research purposes only. Ipamorelin is not approved for human use by the FDA or any equivalent regulatory body.",
    },
    {
      type: "heading",
      text: "Background: Ipamorelin's Mechanism",
    },
    {
      type: "paragraph",
      text: "Ipamorelin stimulates GH release by binding to the ghrelin receptor (GHS-R1a) on somatotroph cells of the anterior pituitary. This pathway is independent of — and synergistic with — the GHRH receptor pathway targeted by compounds like CJC-1295 and Sermorelin.",
    },
    {
      type: "list",
      items: [
        "Molecular weight: ~711 Da",
        "Sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2",
        "Half-life: approximately 2 hours in plasma (animal models)",
        "Receptor: GHS-R1a (ghrelin receptor)",
        "Selectivity: High for GH; minimal cortisol, ACTH, or prolactin stimulation at research doses",
        "Downstream: GH → hepatic IGF-1 production → anabolic/metabolic downstream signaling",
      ],
    },
    {
      type: "heading",
      text: "Step 1: Quality Verification",
    },
    {
      type: "paragraph",
      text: "Before beginning a protocol, confirm the COA (Certificate of Analysis) covers the following:",
    },
    {
      type: "list",
      items: [
        "HPLC purity ≥99% — Ipamorelin's small size makes impurity concentration relatively easy to detect",
        "Mass spectrometry confirmation — MW should be approximately 711 Da",
        "Endotoxin testing (LAL) — critical for any in vivo research",
        "Lyophilized form — optimal for storage stability",
        "Third-party or independent verification — not solely supplier-generated",
      ],
    },
    {
      type: "heading",
      text: "Step 2: Reconstitution",
    },
    {
      type: "paragraph",
      text: "Ipamorelin is typically reconstituted in bacteriostatic water or sterile 0.9% saline. It is generally easy to reconstitute due to its small molecular size and good aqueous solubility.",
    },
    {
      type: "subheading",
      text: "Protocol",
    },
    {
      type: "list",
      items: [
        "Draw diluent into a sterile syringe (29–31 gauge recommended)",
        "Inject diluent slowly against the inside vial wall, not directly onto the powder",
        "Gently swirl or rotate — do not shake",
        "Solution should dissolve quickly (within 30–60 seconds typically)",
        "Resulting solution: clear and colorless — discard if cloudy",
        "Label with reconstitution date and concentration",
      ],
    },
    {
      type: "paragraph",
      text: "Common working concentration: 2 mg Ipamorelin reconstituted in 2 mL bacteriostatic water yields 1 mg/mL. Many protocols work with 500 mcg/mL (2 mg in 4 mL) to allow precise low-dose administration.",
    },
    {
      type: "heading",
      text: "Step 3: Route of Administration",
    },
    {
      type: "paragraph",
      text: "Ipamorelin is most commonly studied via subcutaneous injection in rodent models, which provides consistent absorption and mimics clinical administration patterns:",
    },
    {
      type: "table",
      headers: ["Route", "Notes", "Research Applications"],
      rows: [
        ["Subcutaneous (SC)", "Most studied; consistent bioavailability", "GH pulse studies, body composition, sleep"],
        ["Intraperitoneal (IP)", "Faster systemic uptake; common in acute GH pulse studies", "Short-term GH secretion studies"],
        ["Intravenous (IV)", "Used for pharmacokinetic studies", "PK/PD characterization"],
        ["Intranasal", "Experimental; bioavailability data limited", "CNS-targeted research models"],
      ],
    },
    {
      type: "heading",
      text: "Step 4: Dosing Ranges From Published Research",
    },
    {
      type: "callout",
      text: "All dosing data below is from preclinical animal studies. These are not clinical or human dosing guidelines.",
    },
    {
      type: "paragraph",
      text: "Ipamorelin dosing in indexed preclinical literature spans the following ranges:",
    },
    {
      type: "list",
      items: [
        "100–300 µg/kg SC/IP — low range; used in some selectivity and receptor characterization studies",
        "500 µg/kg — mid range; commonly referenced in comparative GHS studies",
        "1,000 µg/kg (1 mg/kg) — used in some body composition and metabolic studies",
        "Frequency: Once or twice daily, typically around active/sleep transitions in circadian-sensitive models",
        "Duration: 2–12 weeks depending on endpoint (GH pulse studies shorter; body composition/bone studies longer)",
      ],
    },
    {
      type: "paragraph",
      text: "In Elbrønd et al. (1999), Ipamorelin at 500 µg/kg demonstrated dose-dependent GH secretion in swine with significantly higher selectivity for GH vs. cortisol and prolactin compared to GHRP-2 and GHRP-6 at equivalent doses. This selectivity finding underpins much of the subsequent interest in Ipamorelin for longer-duration research protocols.",
    },
    {
      type: "heading",
      text: "Step 5: Timing Considerations for GH Axis Research",
    },
    {
      type: "paragraph",
      text: "GH secretion follows a pulsatile, circadian pattern regulated by sleep, fasting state, and somatostatin tone. Timing of Ipamorelin administration in research significantly affects outcome data:",
    },
    {
      type: "list",
      items: [
        "Fasted state: GH response is typically amplified when animals have not recently eaten",
        "Sleep-associated window: GH pulses in rodents peak during light-phase sleep; timing injections to align with this period may increase observed GH peaks",
        "Post-meal: Elevated insulin suppresses GH secretion — administration shortly after feeding blunts the Ipamorelin-stimulated peak",
        "Interval from last injection: Tachyphylaxis (receptor downregulation) from too-frequent GHS dosing can reduce response; most published protocols space injections 8–12+ hours apart",
      ],
    },
    {
      type: "heading",
      text: "Step 6: CJC-1295 + Ipamorelin — Combination Protocol Considerations",
    },
    {
      type: "paragraph",
      text: "The most studied context for Ipamorelin in the literature involves co-administration with a GHRH analog (CJC-1295 or Sermorelin). The dual-pathway mechanism — GHRH receptor activation (CJC-1295) + GHS-R1a activation (Ipamorelin) — produces synergistic GH release exceeding either compound alone.",
    },
    {
      type: "list",
      items: [
        "CJC-1295 (no DAC): administered SC 1–2x daily; short half-life (~30 min) requires consistent timing",
        "CJC-1295 (with DAC): administered once weekly due to albumin binding extending half-life to ~6–8 days",
        "Ipamorelin: typically administered 1–2x daily regardless of CJC-1295 variant used",
        "When combining: administer simultaneously or within minutes of each other to maximize dual-pathway synergy",
      ],
    },
    {
      type: "heading",
      text: "Step 7: Storage",
    },
    {
      type: "list",
      items: [
        "Lyophilized Ipamorelin: store at -20°C for long-term stability",
        "Reconstituted with bacteriostatic water: 4°C refrigeration; use within 28–30 days",
        "Reconstituted with sterile saline: use within 7 days",
        "Avoid freeze-thaw cycles after reconstitution",
        "Protect from prolonged light exposure",
      ],
    },
    {
      type: "heading",
      text: "Step 8: Endpoint Tracking",
    },
    {
      type: "subheading",
      text: "GH Axis and Endocrine Endpoints",
    },
    {
      type: "list",
      items: [
        "Serum GH: collected at defined intervals post-injection; requires rapid processing (GH is unstable at room temperature)",
        "Serum IGF-1: downstream marker of GH axis activity; more stable than GH; measured at study midpoint and endpoint",
        "Serum cortisol and prolactin: for selectivity confirmation — should not significantly elevate with Ipamorelin",
        "GHRH and somatostatin levels: for mechanistic studies on feedback regulation",
      ],
    },
    {
      type: "subheading",
      text: "Body Composition Endpoints (Longer Studies)",
    },
    {
      type: "list",
      items: [
        "DEXA scanning (body fat %, lean mass) — gold standard in rodent body composition studies",
        "Body weight tracking throughout study",
        "Food intake monitoring — Ipamorelin unlike GHRP-6 does not significantly increase appetite in most studies",
        "Organ weight at necropsy (liver, spleen, thymus)",
        "Bone density (µCT or DEXA) for long-duration studies examining GH/IGF-1 effects on bone",
      ],
    },
    {
      type: "subheading",
      text: "Sleep and Circadian Studies",
    },
    {
      type: "list",
      items: [
        "Polysomnography-equivalent EEG/EMG monitoring in rodent models",
        "Slow-wave sleep (SWS) percentage — key endpoint given GH/sleep relationship",
        "Circadian activity monitoring: running wheel, infrared beam crossing",
      ],
    },
    {
      type: "heading",
      text: "Key Research Findings: Summary",
    },
    {
      type: "table",
      headers: ["Study Area", "Key Finding", "Publication"],
      rows: [
        ["GHS Selectivity", "Ipamorelin selectively stimulates GH with minimal cortisol/prolactin effect", "Elbrønd et al., 1999 (Endocrinology)"],
        ["Bone density", "Ipamorelin increased bone mineral content in ovariectomized rats", "Svensson et al., 2000 (Growth Hormone & IGF Research)"],
        ["GI motility", "GHS-R1a activation by Ipamorelin increased gastric emptying rates in animal models", "Thielemans et al., 2005"],
        ["Fat loss", "GH-mediated lipolysis observed in body composition studies", "Multiple preclinical models"],
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Ipamorelin's well-characterized selectivity, manageable reconstitution requirements, and extensive preclinical literature make it an accessible entry point for GH axis research. Key protocol success factors include: verified purity material, fasting-state or circadian-timed administration, consistent injection intervals to avoid tachyphylaxis, and appropriate endpoint timing for the relatively short half-life. For researchers exploring the dual-pathway GH stimulation hypothesis, combining Ipamorelin with a GHRH analog represents the most studied and documented approach in the literature.",
    },
    {
      type: "callout",
      text: "For research purposes only. Not intended for human use, diagnosis, or treatment.",
    },
  ],
};
